Versican—a protein involved in cancer cell migration—is a driver of lung metastasis in bladder cancer, Dan Theodorescu, MD, PhD, and associates reported online ahead of print in The Journal of Clinical Investigation.
High levels of versican are associated with poor prognosis in patients with bladder cancer, and Dr. Theodorescu’s team found that another protein, RhoGDI2, reduced the expression of versican and suppressed lung metastasis.
Further analysis indicated that RhoGDI2 suppressed metastasis by altering inflammation in the tumor microenvironment. The investigators also discovered that versican’s ability to attract the macrophages that help cancer cells to thrive and metastasis to occur relies on a third protein, CCL2. Drugs that inhibit this protein are already in clinical trials for other conditions.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.